Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AC Immune SA Board/Management Information 2023

Jul 26, 2023

33296_ffr_2023-07-26_3498cda1-2240-4ef9-8b8d-2e5e1e699fdb.zip

Board/Management Information

Open in viewer

Opens in your device viewer

6-K 1 dp197159_6k.htm FORM 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2023

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park Building B 1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

On July 26, 2023, AC Immune SA (the “Company”) issued a press release announcing the appointment of Nuno Mendonça, MD. Effective October 1, 2023, Dr. Mendonça will join the Company as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, currently Chief Medical Officer, will leave at the end of September. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.

This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333- 255576, File No. 333-227016 and File No. 333-249655) and Form S-8 (File No. 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Field: Page; Sequence: 2

Field: /Page

EXHIBIT INDEX

| Exhibit
Number | Description |
| --- | --- |
| 99.1 | Press Release, dated July 26, 2023 |

Field: Page; Sequence: 3

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA — By: /s/ Andrea Pfeifer
Name: Andrea Pfeifer
Title: Chief Executive Officer
By: /s/ Christopher Roberts
Name: Christopher Roberts
Title: Vice President, Finance and Interim Chief Financial Officer

Date: July 26, 2023

Field: Page; Sequence: 4; Options: Last

Field: /Page